CIK 0001615219 · Non-accelerated filer<br>Smaller reporting company
Decoy Therapeutics Inc.
Sign in to watch- Ticker
- DCOY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465087339
- Phone
- 346-772-0346
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
- Former names
- Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Burleson Tess Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-02-20 | HANISH ARNOLD C Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2023-02-13 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +6,432 | 21,851 | ||
| 2023-02-13 | Arthur David J. Chief Executive Officer | Grant or award | +14,300 | 48,019 | ||
| 2023-01-03 | Lieber Jonathan I Director | Grant or award | +1,440 | 2,940 | ||
| 2023-01-03 | McCreedy Bruce J Jr. Director | Grant or award | +1,440 | 1,788 | ||
| 2023-01-03 | HANISH ARNOLD C Director | Grant or award | +1,440 | 1,440 | ||
| 2023-01-03 | Lammers Paul Director | Grant or award | +1,440 | 1,718 | ||
| 2023-01-03 | Burleson Tess Director | Grant or award | +1,440 | 2,722 | ||
| 2023-01-03 | McVicar William K. Director | Grant or award | +1,440 | 1,788 | ||
| 2023-01-03 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +8,000 | 15,419 | ||
| 2023-01-03 | Arthur David J. Chief Executive Officer | Grant or award | +20,000 | 33,719 | ||
| 2022-11-03 | Arthur David J. Chief Executive Officer | Grant or award | +2,693 | $1.73 | $5K | 13,719 |
| 2022-11-03 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +1,488 | $1.73 | $3K | 7,419 |
| 2022-11-03 | Arthur David J. Chief Executive Officer | Grant or award | +10,000 | $1.73 | $17K | 21,026 |
| 2022-11-03 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +7,314 | $1.73 | $13K | 13,245 |
| 2022-11-03 | Arthur David J. Chief Executive Officer | Grant or award | +10,000 | $1.73 | $17K | 285,674 |
| 2022-11-03 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +7,314 | $1.73 | $13K | 155,633 |
| 2022-06-07 | Burleson Tess Director | Purchase | +27,700 | $0.18 | $5K | 32,050 |
| 2022-06-07 | Lieber Jonathan I Director | Purchase | +37,500 | $0.19 | $7K | 37,500 |
Page 2 of 6 · 107 trades